Vitiligo
☆ An den 2022 Stiftung Warentest Resultater aus Däitschland war d'Zefriddenheet vum Konsument mam ModelDerm nëmme liicht manner wéi mat bezuelte Telemedizin Konsultatiounen.
Vitiligo vun de Fanger ass méi schwéier ze behandelen wéi aner Beräicher. Ausser datt et kosmetesch onsiichtlech ass, ass Vitiligo normal an ass net ustiechend. An der Dermatologie ass déi effektivst Behandlung Phototherapie oder Laserbehandlung (Excimer) 2-3 Mol pro Woch fir mindestens 1 Joer. Wann Dir aus finanzielle Grënn net dacks an d'Spidol kënnt oder well Dir beschäftegt sidd, kënnt Dir eng Phototherapie-Maschinn probéieren, déi fir Hausgebrauch guttgeheescht ass.
Eyellid vitiligo
Vitiligo op der Hand
References
Vitiligo ass eng allgemeng Hautkrankheet déi Flecken vu wäisser Haut verursaacht wéinst dem Verloscht vu Melanozyten. Rezent Fuerschung weist datt et eng Autoimmun Krankheet ass. Och wann et dacks als kosmetesch Thema gesi gëtt, kann et déif mental Wuelbefannen an alldeeglecht Liewen beaflossen. Am Joer 2011 hunn d'Experten en Typ genannt segmental vitiligo getrennt vun aneren klasséiert.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Aktive Vitiligopatienten hunn verschidde Therapieoptiounen, wéi systemesch Glukokortikoiden, Phototherapie a systemesch Immunosuppressiva. Stabile Vitiligopatienten kënnen Erliichterung vun topeschen Kortikosteroiden, topesch Calcineurin-Inhibitoren, Phototherapie an Transplantatiounsprozeduren fannen. Rezent Fortschrëtter am Verständnis vun de Basisdaten vu Vitiligo hunn zu der Entwécklung vu geziilten Therapien gefouert. De Moment sinn JAK-Inhibitoren déi villverspriechend, déi gutt Tolerabilitéit a funktionell Resultater ubidden, trotz dem Risiko fir latente Infektiounen a systemesch Nebenwirkungen ze aktivéieren, déi allgemeng mat aneren immunosuppressive Agenten sinn. Lafend Fuerschung zielt fir Schlëssel Zytokine ze identifizéieren déi an der Entwécklung vu Vitiligo involvéiert sinn (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . D'Blockéierung vun dësen Zytokine huet Verspriechen an Déieremodeller an e puer Patienten gewisen. Zousätzlech sinn Ermëttlungen iwwer miRNA-based therapeutics an adoptive Treg cell therapy amgaang.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Et gëtt keng bekannt Kur fir Vitiligo. Fir déi mat hell Haut, Sonneschutz a Make-up sinn alles wat normalerweis recommandéiert ass. Aner Behandlungsoptioune kënnen Steroidcremen oder Phototherapie enthalen.
○ Behandlung
#Phototherapy
#Excimer laser
#Tacrolimus ointment